BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
Status:
Completed
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod
administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy
with persistent proteinuria of between 1-6 g/day.